| Name | Title | Contact Details |
|---|
Intervet/ Schering-Plough Animal Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2004, Direct Flow Medical®, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing patient complications. The company is exploring application of its proprietary technology beyond the aortic valve, to the mitral valve and other valve anatomy. Headquartered in Santa Rosa, California, the company also has technology and manufacturing facilities in Lake Forest, California. The Direct Flow Medical TAVI system received the CE Mark in January 2013 and is currently available commercially in Europe. Company Culture: Direct Flow Medical, Inc. has a very unique corporate culture and has developed a set of principles that makes this a unique place to work. Our company is a community, and people feel best when they are proud of their community and know that it is accomplishing something worthwhile. Our employees are encouraged to get to know one another and to support one another in their achievements. We acknowledge and celebrate professional goals as well as personal milestones. The atmosphere at Direct Flow Medical, Inc. is one that supports both a sense of satisfaction from our work, and also a sense of companionship with our co-workers.
It is the vision of Willow Crest hospital to be the provider of choice for patients, family members, and referral sources. We shall strive to exceed expectations of our customers in the provision of high quality, cost effective services.
Therapy Pros, LLC is a Bloomfield Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.